-+ 0.00%
-+ 0.00%
-+ 0.00%

Livzon Subsidiary MABPharm Wins China Approval for Phase I Trial of Anti-FXI Antibody

PUBT·10/27/2026 08:51:11
Livzon Subsidiary MABPharm Wins China Approval for Phase I Trial of Anti-FXI Antibody
  • Livzon Pharmaceutical's subsidiary Livzon MABPharm secured Chinese regulatory clearance for clinical trials of its recombinant humanized anti-FXI bispecific antibody injection.
  • The treatment, LZSN2501, targets prevention of venous thromboembolism following total knee arthroplasty.
  • The Phase I trial will evaluate single ascending doses in healthy adults in China, assessing safety, tolerability, pharmacokinetics and pharmacodynamics.
  • Cumulative direct research and development spending on the product totaled approximately RMB 28.24 million as of October 27, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livzon Pharmaceutical Group Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261027-12384144), on October 27, 2026, and is solely responsible for the information contained therein.